Literature DB >> 10051461

Elevated circulating cardiac troponin I in patients with cirrhosis.

D Pateron1, P Beyne, T Laperche, D Logeard, P Lefilliatre, P Sogni, R Moreau, P Langlet, A Elman, J Bernuau, D Valla, S Erlinger, D Lebrec.   

Abstract

It has been shown that certain patients with cirrhosis have asymptomatic cardiac abnormalities that have not yet been explained. Thus, cardiac troponin I, a specific marker of myocardial injury, has been measured in patients with cirrhosis without previous cardiac disease. Thirty-two consecutive patients (age 49 +/- 11) with cirrhosis and normal ECG were selected, 22 of which were alcoholic. Hemodynamic investigations were performed. Left ventricular function and mass were evaluated by echocardiography. Serum creatine kinase MB mass, myoglobin, and cardiac troponin I concentrations were measured. Cardiac troponin I concentrations were elevated in 10 patients (32%) (range 0.06-0.25 microg/L) whereas creatine kinase MB mass and myoglobin were normal in all patients. Abnormal troponin I values were not related to the severity of cirrhosis, to the degree of portal hypertension, or to other hemodynamic values. In contrast, elevated serum cardiac troponin I concentrations were related to a decreased stroke-volume index (P <. 05) and a decreased left ventricular mass (P <.05). These results show a high prevalence of slightly elevated serum cardiac troponin I in patients with cirrhosis, especially in those with alcoholic cirrhosis. Elevated troponin I is associated with subclinical left ventricular myocardial damage. These findings may be linked to a lack of left ventricular adaptation in certain patients with cirrhosis and alcoholic cardiomyopathy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10051461     DOI: 10.1002/hep.510290332

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  12 in total

Review 1.  Cardiohepatic syndrome.

Authors:  Gerhard Poelzl; Johann Auer
Journal:  Curr Heart Fail Rep       Date:  2015-02

Review 2.  Cirrhotic cardiomyopathy: a pathophysiological review of circulatory dysfunction in liver disease.

Authors:  S Møller; J H Henriksen
Journal:  Heart       Date:  2002-01       Impact factor: 5.994

3.  Cirrhotic cardiomyopathy.

Authors:  Florence Wong
Journal:  Hepatol Int       Date:  2008-11-11       Impact factor: 6.047

4.  NT-proBNP and Echocardiographic Parameters in Liver Cirrhosis - Correlations with Disease Severity.

Authors:  Alexandru Radu Mihailovici; Ionuț Donoiu; Dan Ionuț Gheonea; Oana Mirea; Georgică Costinel Târtea; Maria Buşe; Veronica Calborean; Cosmin Obleagă; Vlad Pădureanu; Octavian Istrătoaie
Journal:  Med Princ Pract       Date:  2019-04-16       Impact factor: 1.927

5.  Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease.

Authors:  J H Henriksen; J P Gøtze; S Fuglsang; E Christensen; F Bendtsen; S Møller
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

Review 6.  Cirrhotic cardiomyopathy.

Authors:  Luis Ruiz-del-Árbol; Regina Serradilla
Journal:  World J Gastroenterol       Date:  2015-11-07       Impact factor: 5.742

7.  The end-organ impairment in liver cirrhosis: appointments for critical care.

Authors:  Antonio Figueiredo; Francisco Romero-Bermejo; Rui Perdigoto; Paulo Marcelino
Journal:  Crit Care Res Pract       Date:  2012-05-16

Review 8.  Cirrhotic cardiomyopathy.

Authors:  Soon Koo Baik; Tamer R Fouad; Samuel S Lee
Journal:  Orphanet J Rare Dis       Date:  2007-03-27       Impact factor: 4.123

9.  Cardiac troponin elevation predicts mortality in patients undergoing orthotopic liver transplantation.

Authors:  David Snipelisky; Sean Donovan; Michael Levy; Raj Satyanarayana; Brian Shapiro
Journal:  J Transplant       Date:  2013-07-14

10.  Beckman Access versus the Bayer ACS:180 and the Abbott AxSYM cardiac Troponin-I real-time immunoassays: an observational prospective study.

Authors:  Robert H Baevsky; Rajesh K Kapur; Howard A Smithline
Journal:  BMC Emerg Med       Date:  2004-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.